We are an early stage drug discovery company using a novel, natural products-based high throughput screening approach to identify drug leads
Natural products (NP) or their derivatives have been our best pharmaceuticals but are difficult to supply in numbers sufficient for high throughput screening (HTS). We use a synthetic biology approach to produce libraries of millions of natural products suitable for HTS. We screen these libraries in high throughput animal screens for leads to be developed into drugs to treat diseases for which few or no therapeutic options exist.
We use a synthetic biology approach to create immense libraries of natural products suitable for high throughput screening. This is a technology initially developed by University of Utah researchers, for which we licensed and developed further. This allows for high throughput screening of natural products in ways not previously possible. Furthermore, we screen these libraries in high throughput, “whole animal” screens for drug leads. The ability to screen in whole animals allow drug leads to be identified with good ADME-tox properties. Leads with poor ADME-tox properties are eliminated from the beginning. This means that our leads are less likely to fail during development or during late-stage clinical testing.